v3.21.2
Condensed Consolidated Statements of Operations (Unaudited) - USD ($)
$ in Thousands
3 Months Ended 9 Months Ended
Sep. 30, 2021
Sep. 30, 2020
Sep. 30, 2021
Sep. 30, 2020
Income Statement [Abstract]        
Revenue $ 200 $ 200
Cost of revenue 144 144
Gross profit 56 56
Operating expenses:        
Commercial operations 2,432 687 5,792 1,532
General and administrative 5,987 2,222 16,100 6,942
Research and development 5,305 2,619 12,878 7,321
Total operating expenses 13,724 5,528 34,770 15,795
Loss from operations (13,668) (5,528) (34,714) (15,795)
Other income (expense):        
Interest expense (53)
Change in fair value - Senior Secured Convertible Notes and Senior Convertible Note 367 1,682 (5,521)
Offering costs - Senior Secured Convertible Note and Senior Convertible Note (50) (660)
Debt extinguishments loss - Senior Secured Convertible Notes (663) (3,715) (4,600)
Debt forgiveness 300
Other income (expense), net (346) (1,733) (10,834)
Loss before provision for income tax (13,668) (5,874) (36,447) (26,629)
Provision for income taxes
Net loss before noncontrolling interests (13,668) (5,874) (36,447) (26,629)
Net loss attributable to the noncontrolling interests 1,441 391 3,318 1,093
Net loss attributable to PAVmed Inc. (12,227) (5,483) (33,129) (25,536)
Less: Series B Convertible Preferred Stock dividends earned (67) (74) (216) (215)
Net loss attributable to PAVmed Inc. common stockholders $ (12,294) $ (5,557) $ (33,345) $ (25,751)
Per share information:        
Net loss per share attributable to PAVmed Inc. - basic and diluted $ (0.15) $ (0.11) $ (0.41) $ (0.56)
Net loss per share attributable to PAVmed Inc. common stockholders – basic and diluted $ (0.15) $ (0.11) $ (0.42) $ (0.57)
Weighted average common shares outstanding, basic and diluted 83,307,170 48,380,677 79,873,583 45,563,961

Source